ClinicalTrials.gg
CompletedNCT03755544SUNNYUpdated Feb 28, 2020

Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD

An observational study in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-28.

Sponsored by Orion Corporation, Orion Pharma · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
231
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Started
2019
the only one that year
Observational
2 of 21
none open now
Registered
18th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the only one that started in 2019, is one of 2 observational ones, and was the 18th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone Easyhaler to achieve and maintain asthma or COPD control.

Read the detailed description

A prospective, open-label, non-interventional, multicentre study in adult patients with asthma or COPD who are treated with Salmeterol/fluticasone Easyhaler. During the study the Salmeterol/fluticasone Easyhaler will be used according to the Summary of Product Characteristics. Clinical effectiveness of the treatment will be evaluated with change in asthma or COPD symptoms during 12 weeks treatment.

03

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients will be enrolled by physicians from outpatient clinics

Eligibility criteria

Main Inclusion Criteria:

  1. Male or female patients with asthma or who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the study
  2. Age ≥18 years.
  3. Written obtained.

Main Exclusion Criteria:

  1. Pregnant or lactating female patients.
  2. Participation in other clinical studies during the study.
  3. Known (allergy) to salmeterol, fluticasone propionate or the lactose
  4. Any significant medical disease or condition or other factor that might interfere with study assessments or study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
231 participants (actual)
Patient registry
No

Groups and cohorts

  • Asthma patients

    Male or female patients with diagnosed asthma who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler. During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC).

  • COPD patients

    Male or female patients with diagnosed COPD who have been using salmeterol/fluticasone propionate combination treatment for at least 3 months before the beginning of the study, and for whom the decision has already been made to switch to Salmeterol/fluticasone Easyhaler. During the study, the Salmeterol/fluticasone Easyhaler will be used according to the local Summary of Product Characteristics (SmPC).

06

What researchers measure

Primary outcomes

  1. Asthma Control Test (ACT)

    A multiple-choice questionnaire for patients with asthma, each choice is assigned a score 1-5. There are 5 questions to answer. The total score is calculated, ranging between 5 and 25. Lower scores indicate worse asthma control.

    Time frame: 12 weeks

  2. COPD Assessment Test (CAT)

    A bipolar questionnaire for patients with COPD, there are 8 questions with 2 answers showing different extremes, respondents choose the numbered answer that reflects their opinion (in the range 0-5). The total score is calculated and ranges between 0 and 40. Higher scores indicate worse COPD control.

    Time frame: 12 weeks

Secondary outcomes

  1. Asthma symptom control assessment

    A dichotomous questionnaire for patients with asthma, there are 4 questions with 'Yes' or 'No' answers, respondents choose the answer that reflects their opinion. A great number of 'Yes' answers indicate worse asthma control.

    Time frame: 12 weeks

  2. Forced expiratory volume in one second (FEV1)

    from spirometry

    Time frame: 12 weeks

  3. Feeling of Satisfaction with Inhaler questionnaire (FSI-10)

    patient's satisfaction with inhaler

    Time frame: 12 weeks

  4. A questionnaire to assess Physician's/nurse's perception of Salmeterol/fluticasone Easyhaler overall use

    A multiple-choice questionnaire for the physician/nurse, completed for each patient. Evaluation will be by frequency tables and summary statistics.

    Time frame: 12 weeks

  5. Mini-AQLQ questionnaire

    A multiple-choice questionnaire for patients with asthma, each choice is assigned a score 1-7. There are 15 questions to answer. The total score is calculated and ranges between 15 and 105. Lower scores indicate worse quality of life.

    Time frame: 12 weeks

  6. Health care utilisation questionnaire

    A dichotomous questionnaire for all patients, there are 6 questions, with 'Yes' or 'No' answers, to collect health care use. Evaluation will be by frequency tables and summary statistics.

    Time frame: 24 weeks

  7. Modified Medical Research Council (mMRC) dyspnea questionnaire

    A bipolar questionnaire for patients with COPD, there is one question with 5 choices between two extremes, respondents choose the answer that reflects their opinion (in the range 0-4).. Higher scores indicate worse dyspnea symptoms.

    Time frame: 12 weeks

  8. Symptom burden and exacerbation risk assessment (ABCD classification)

    Patients will be assessed by the physician, based on symptoms and exacerbation history according to the ABCD classification scheme (GOLD, 2018).

    Time frame: 12 weeks

  9. Forced vital capacity (FVC)

    from spirometry

    Time frame: 12 weeks

07

Study locations

1 site
  • Lungenpraxis
    Hamburg, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Feb 2020, 12 months.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 12 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2018
First posted
Nov 28, 2018
StartActual
Jan 16, 2019
Primary completionActual
Feb 13, 2020
CompletionActual
Feb 13, 2020
Last update
Feb 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03755544
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Jan 16, 2019
Primary completion
Feb 13, 2020
Completion
Feb 13, 2020
Last update
Feb 28, 2020

Study contacts

Orion Pharma Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion